Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-label, randomized, single dose, three-way crossover, six sequence pilot study to evaluate the relative bioavailability of one amlodipine 10 mg tablet and rosuvastatin 20 mg tablet to two fixed dose combination tablet formulations of amlodipine (10 mg) and rosuvastatin (20 mg) in healthy adult male and female subjects under fasting conditions

Next Previous
Trial Profile

An open-label, randomized, single dose, three-way crossover, six sequence pilot study to evaluate the relative bioavailability of one amlodipine 10 mg tablet and rosuvastatin 20 mg tablet to two fixed dose combination tablet formulations of amlodipine (10 mg) and rosuvastatin (20 mg) in healthy adult male and female subjects under fasting conditions

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 03 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amlodipine/rosuvastatin (Primary) ; Amlodipine; Rosuvastatin
  • Indications Hypertension
  • Focus Pharmacokinetics
  • Sponsors GlaxoSmithKline; GSK

Most Recent Events

  • 01 Mar 2016 Results published in the Clinical Pharmacology in Drug Development.
  • 25 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
  • 13 Jun 2014 Planned End Date changed from 1 Jun 2014 to 1 Jul 2014 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top